First Glivec biosim gets EMA panel backing; Dr. Reddy's snaps up OctoPlus for $36M;

@FiercePharma: Merck is a champion donor, charity pub says. Ranks 2nd for corporate giving, as % of pretax profits.--Forbes. More | Follow @FiercePharma

> European regulators recommended approving Teva Pharmaceutical Industries' ($TEVA) biosimilar version of the Novartis ($NVS) cancer drug Glivec. Report

> India's Dr. Reddy's plans to pay $36 million to buy the Dutch injectables drug firm OctoPlus. Report

> Bayer said its Xarelto blood thinner won European committee backing for a new use in treating pulmonary embolism and for preventing recurrent deep vein thrombosis. Report

> Astellas Pharma launched the hormone-blocking treatment Gonax for prostate cancer in Japan. Report

> Supernus Pharmaceuticals ($SUPN) won FDA approval for its epilepsy drug Oxtellar XR, its second FDA nod since it went public in May. Report

> Medicare's policies on compounded drugs are coming under scrutiny in the wake of a meningitis outbreak linked to a big compounding pharmacy. Report

Medical Device News

 @FierceMedDev: Israel's growing medical device industry gains a public stage this week. More | Follow @FierceMedDev

 @MarkHFierce: W.L. Gore has the final piece in place for its REDUCE Clinical study, to test a new stroke prevention device. More | Follow @MarkHFierce

 @DamianFierce: WuXi AppTec is making a splash in biologics, launching a cGMP plant in China. More | Follow @DamianFierce

> Edwards wins broader FDA approval for Sapien heart valve. More

> Wright takes down knee website after Stryker suit. Story

Biotech News

 @FierceBiotech: Researchers seek new pancreatic cancer biomarkers. Item | Follow @FierceBiotech

 @JohnCFierce: In case you missed it Friday, my analysis on Q3 venture numbers (good) and top 10 deals of the quarter. Special Report | Follow @JohnCFierce

 @RyanMFierce: Quintiles reels in pharma business with IT game changers. More | Follow @RyanMFierce

> Orexigen says FDA nods support for a speedy review of Contrave. More

> Genzyme pays $22.5M upfront to bag Asian rights to Alnylam's hot ATTR program. Report

> Bayer nails promising PhIII results for new PAH contender riociguat. News

CRO News

> Lundbeck seeks partners on Alzheimer's drug after EMA rejection. Item

> Korean group enlists WCCT to spur drug development. More

> WuXi launches China's first GMP-friendly biologics plant. News

> Catalent looks to bridge industry, academia on drug delivery. Article

Biotech IT News

> Pfizer wins popularity contest in social media survey of patients. More

> Quintiles reels in pharma business with IT game changers. Story

> Appistry grabs distribution of MIT-Harvard genome toolkit. Report

> Big Pharma consortium to share cancer trial data. Article

And Finally... A new study found that diet and weight loss didn't prevent heart attacks and other problems in diabetics, but they may cut the number of necessary medications. Report

Suggested Articles

The FDA has slapped a U.S. drug repackager, saying in a warning letter that its storage processes and equipment cleaning are not up to expectations.

By extending the tender offer for just six days, Roche seems confident it will receive positive reviews from U.S. and U.K. watchdogs in time.

Back in June, Takeda scrapped a Ninlaro trial in rare disease light-chain (AL) amyloidosis. Saturday, it shared the data behind the decision.